Back to News
Market Impact: 0.3
FDA Approves Teva's Once-Monthly Injectable Olanzapine
Source: Nasdaq
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Teva Pharmaceuticals announced that the U.S. FDA approved WELTRUZA (olanzapine) extended-release injectable suspension for adults with schizophrenia. The article provides no launch timing, sales outlook, or financial estimates.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
TEVA0.75
More News
- Teva wins FDA approval for monthly schizophrenia injection Weltruza
- Stocks making the biggest moves midday: T-Mobile, Verizon, AT&T, Crown Castle, Teva & more
- J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold?
- Wall Street Week | Michigan Manufacturing, AI Debt Investments, Baby Bonds, Canadian Coal Fight
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback
- SpaceX makes big move into wireless. These once 'obsolete' tech stocks could benefit
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Tools for CFA Charterholders: An Evidence Standard
- Weekly Update: Unstructured Data Search, Ask AI, and Advanced Futures Data